Given the fact that PSMA ligands can be used to image diseases other than prostate cancer (32–34), their safety and biodistribution in women have to be established for regulatory purposes if one might conduct studies or seek market authorization for other indications. This evidence concerns the gene FOLH1 and Familial prostate cancer.